Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

39.81 -7.61 (-16.04%)
Streaming Delayed Price Updated: 1:30 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
News headline image
Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The Stock ↗
Jaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients treated with Jaypirca experienced their cancer shrink or disappear after... 
Via Stocktwits
News headline image
What's Going On With Eli Lilly Stock On Tuesday? ↗
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, with more data expected. 
Via Benzinga
News headline image
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views ↗
 
Via Benzinga
Topics Earnings
News headline image
Novo Nordisk Stock Slumps After Slashing Full-Year Guidance, But Retail Has Its Eyes On An Oral Weight Loss Drug ↗
The company now expects full-year sales growth of 8% to 14% at a constant exchange rate, down from its previous estimate of 13% to 21%. 
Via Stocktwits
News headline image
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting? ↗
Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO. 
Via Benzinga
News headline image
Novo Nordisk Falls On Lowered Guidance. Pharma Giant Names New CEO. ↗
Novo Nordisk lowered its full-year guidance and named a new CEO. The pharma giant's shares plunged in early trades. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO ↗
Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales. 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
3 Surprisingly Underrated Stocks to Buy Right Now ↗
These big pharma stocks arguably aren't receiving the respect they deserve. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Healthcare Stocks That Are Losing to the S&P 500 This Year ↗
Wall Street might be underestimating these companies' potential. 
Via The Motley Fool
Topics Stocks
News headline image
Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China ↗
More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the American market. 
Via Benzinga
Topics Law Enforcement Supply Chain
News headline image
Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case ↗
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, contributory, and induced infringement claims. 
Via Benzinga
Topics Intellectual Property
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Meets Caviar Cruise Standards for Quality Investing ↗
The Caviar Cruise stock screener identifies top long-term investments like Novo Nordisk (NVO), with strong revenue growth, high ROIC, solid cash flow, and pricing power—ideal for quality investors. 
Via Chartmill
News headline image
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costs ↗
 
Via Benzinga
News headline image
2 Beaten-Down Dividend Growth Stocks to Buy on the Dip ↗
Via The Motley Fool
News headline image
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A potential undervalued opportunity in healthcare ↗
NOVO-NORDISK (NYSE:NVO) appears undervalued with strong profitability, solid growth, and a reasonable valuation, making it a potential candidate for value investors in the healthcare sector. 
Via Chartmill
News headline image
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money ↗
Via The Motley Fool
News headline image
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. ↗
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles ↗
GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs altering consumer purchasing patterns. 
Via Benzinga
News headline image
Hims & Hers Health Is Looking to Cash In on This Novo Nordisk Blunder ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock at a Reasonable Valuation ↗
NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks in the pharmaceutical sector. 
Via Chartmill
News headline image
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Absurdly Cheap Growth Stocks to Load Up On Right Now ↗
Via The Motley Fool
Topics World Trade
News headline image
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes ↗
An update on Sana Biotechnology. 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.